Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Comment by Sextanton Dec 29, 2020 6:54pm
251 Views
Post# 32194126

RE:RE:RE:RE:RE:RE:64.5 million traded at 3.5 cents average

RE:RE:RE:RE:RE:RE:64.5 million traded at 3.5 cents average@Ravens1, I do not work for this company. It’s highly doubtful they could afford me—lol.
I’m what you call a high net worth investor who looks for select opportunities. I have my own network and quite frankly, a lot of others have yet to come in. No one can with any certainty how a stock will react hourly or daily. I like to look at time intervals. I do expect to see the stock trading at multiples assuming good midpoint numbers in February. I do expect to see licensing opportunities in lesser regulated jurisdictions. I do expect to see potential pharma partners and I do expect to see a future uplisting. These expectations are tempered  by execution assumptions. Btw, I’m still buying...
<< Previous
Bullboard Posts
Next >>